FDA leaders in an NEJM article say they're open to innovative trial designs for psychedelic therapies, including non-placebo comparators.
FDA regulators said they’re open to “innovative approaches” for studying the effects of psychedelic therapies, including the use of comparators other than placebo.
The comments …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA finalizes clinical guidance for psychedelic drugs, easing abuse-study requirements, and sets a Sept. 14 hearing on…
Psychedelics as an adjunctive therapy to psychiatric counseling may be feasible for anxiety and mood disorders, but proper…
SAN FRANCISCO — Psychedelics in mental health treatment is a rapidly changing landscape, but it is important for primary care…
The FDA announced regulatory actions Friday to support development of serotonin-2A agonists and related products, including…
As the first psychedelics near approval, several other factors warrant attention to ensure effective and safe implementation.
News and commentary from the psychiatry world
